Ian Magrath - Concepedia

Author

Ian Magrath

Also Known As

Brian E. Huber, I Magrath, I T Magrath, I. Magrath, I. T. MAGRATH, I. T. Magrath, I.T. Magrath, IAN MAGRATH, IAN T. MAGRATH, Ian Magrath

228

Publications

12.9K

Citations

H-Index

178

Concepts

All Affiliations

National Cancer Institute National Institutes of Health International Network for Cancer Treatment and Research Uganda Cancer Institute

About

Ian Magrath is an author at National Cancer Institute specializing in medicine, pathology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	81	7.6K
2	Health Sciences	14	14	1.5K
3	Public Health	4	4	359
4	Engineering	3	3	156
5	Natural Sciences	1	1	108

Ian Magrath

116

Publications

10.7K

Citations

H-Index

Page 1

	Year	Citations
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Gianluca Gaïdano, Paola Ballerini, Jerry Z. Gong, Proceedings of the National Academy of Sciences Chronic Lymphocytic LeukemiaMixed-phenotype Acute LeukemiaImmunologyPathologyP53 Loss/inactivation	1991	896
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Ian Magrath, Magdalena Adde, Aziza Shad, Journal of Clinical Oncology	1996	485
Acute tumor lysis syndrome Lawrence F. Cohen, James E. Balow, Ian Magrath, The American Journal of Medicine HemodialysisUrologyKidney TransplantKidney FailurePathology	1980	432
Paediatric cancer in low-income and middle-income countries Ian Magrath, Eva Steliarova‐Foucher, Sidnei Epelman, The Lancet Oncology MedicineGlobal HealthEpidemiology Of CancerPaediatric CancerPediatrics	2013	416
p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Saijun Fan, Wafik S. El‐Deiry, I Bae, PubMed Dna DamageHuman Lymphoma CellsMutant P53 LinesApoptosisPathology	1994	409
Distinctions Between CD8+ and CD4+ T-Cell Regenerative Pathways Result in Prolonged T-Cell Subset Imbalance After Intensive Chemotherapy Crystal L. Mackall, Thomas A. Fleisher, Margaret R. Brown, Blood	1997	382
Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Pier Giuseppe Pelicci, D M Knowles, Ian Magrath, Proceedings of the National Academy of Sciences Hematological MalignancyChromosomal BreakpointsLymphoid NeoplasiaC-myc Locus DifferHuman C-myc Gene	1986	362
Activation of Suppressor T Cells during Epstein-Barr-Virus-Induced Infectious Mononucleosis Grovanna Tosato, Ian Magrath, Irma R. Koski, New England Journal of Medicine	1979	326
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J. Miser, Timothy J. Kinsella, Timothy J. Triche, Journal of Clinical Oncology Neuro-oncologyMesna UroprotectionSurgical OncologyUrologyRadiation Therapy	1987	324
Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. P M O'Connor, Joany Jackman, D Jondle, PubMed Class IiRadiation EffectPathologyRadiation BiologyCancer Biology	1993	311

Page 1